Davide Capodanno/X
Nov 4, 2025, 09:10
OCCUPI Trial Analysis Highlights Benefits of OCT Guidance in ACS Patients
Davide Capodanno, Professor of Cardiology at University of Catania, editor-in-Chief of EuroIntervention, posted on X.
“In this post hoc analysis of patients with acute coronary syndromes in the OCCUPI trial, the primary outcome—1-year composite of cardiac death, myocardial infarction, stent thrombosis, or ischemia-driven target vessel revascularisation—occurred in 4.9% of the OCT-guided group versus 9.5% in the angiography-guided group (HR 0.50, 95% CI 0.29–0.87; p=0.011; p=0.273 for interaction). Such benefit was particularly observed in patients who achieved stent optimisation by OCT.”
Read ARTICLE here EDITORIAL here.
Stay updated with Hemostasis Today.
-
Feb 24, 2026, 14:01A European Action Plan on Rare Diseases Is a Necessity, Not an Option – EPODIN
-
Feb 24, 2026, 13:59Riitta Lassila: How APAC Impacts the Interplay Between Complement and Coagulation
-
Feb 24, 2026, 13:29Win Ratio Analysis of Edoxaban vs Dalteparin in Cancer-Associated VTE – JTH
-
Feb 24, 2026, 13:28EAHAD Welcomes New Members to the Nurses Committee
-
Feb 24, 2026, 13:25AbQader Bedil: Donor Ferritin Testing and Iron Care
-
Feb 24, 2026, 12:53Tagreed Alkaltham։ Blood Is a Naturally Integrated and Adaptive Physiological System
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss